Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2022-10-21 Investor Presentation
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Q2 FY23 Investor Presentation' and contains detailed financial performance data, segment performance, market mix, and business updates for Glenmark Life Sciences Limited for the second quarter of fiscal year 2023. It includes revenue, EBITDA, PAT, balance sheet items, cash flow, and other operational highlights. The document is about 15,000 characters long, indicating it is a full presentation rather than a brief announcement. The text explicitly refers to it as an 'Investor Presentation' and includes detailed charts and commentary typical of such presentations. There is no indication that this is an annual report, earnings release, or regulatory filing. Therefore, the document fits the category of an Investor Presentation (IP).
2022-10-21 English
Outcome of Board Meeting
Regulatory Filings
2022-10-21 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the National Stock Exchange of India, informing about an upcoming earnings call scheduled for October 21, 2022. It includes details such as date, time, dial-in numbers, and contact information for clarifications. The document does not contain any financial results or substantive financial data itself, but rather serves as an announcement or invitation to the earnings call event. The document length is short (2424 characters), and it primarily serves to notify and invite stakeholders to the call. Therefore, it is not the earnings release itself but an announcement related to the earnings call. According to the filing definitions and rules, this type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other specific categories like Earnings Release (ER) or Call Transcript (CT).
2022-10-17 English
Closure of trading window
Regulatory Filings Classification · 95% confidence The document is a letter dated October 14, 2022, addressed to stock exchanges and referencing a board meeting scheduled for October 21, 2022. The purpose of the meeting is to consider and approve the unaudited financial results for the second quarter and half year ended September 30, 2022. The letter also mentions the closure of the trading window for insider trading compliance. The document does not contain the financial results themselves but is an announcement of the upcoming board meeting and the expected approval of financial results. The document length is short (2273 characters) and it serves as a notification rather than a report. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement about the board meeting and financial results approval, not the actual financial report or earnings release.
2022-10-14 English
Board Meeting — Financial results
Board/Management Information Classification · 95% confidence The document is a letter dated October 14, 2022, addressed to stock exchanges (NSE and BSE) informing about an upcoming Board Meeting scheduled for October 21, 2022. The purpose of the meeting is to consider and approve the unaudited financial results for the second quarter and half year ended September 30, 2022. It also mentions the closure of the trading window for insider trading compliance. The document is short (2273 characters) and serves as a notification of a board meeting and upcoming financial results approval, not the financial results report itself. It does not contain any financial data or detailed analysis. Therefore, it is an announcement related to board/management information, specifically about a board meeting and financial results approval. This fits best under the category 'Board/Management Information (MANG)'.
2022-10-14 English
Annual General Meeting
Regulatory Filings
2022-09-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.